Delcath Systems Announces $25M Buyback Plan
Benzinga Newsdesk 11 months ago
News
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date.